ResMed Inc. 10-Q Summary: Quarter Ended March 31, 1999
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 1999, and the nine-month period ended March 31, 1999. ResMed Inc. designs, manufactures, and markets devices for the evaluation and treatment of sleep-disordered breathing, primarily obstructive sleep apnea. Principal manufacturing operations are located in Australia, with major distribution and sales sites in the United States, the United Kingdom, and Europe.
Key Financial Metrics
| Metric | 9 Months Ended Mar 31, 1999 | 9 Months Ended Mar 31, 1998 | 3 Months Ended Mar 31, 1999 | 3 Months Ended Mar 31, 1998 |
|---|---|---|---|---|
| Net Revenue | $63.5 million | $47.2 million | $22.8 million | $17.1 million |
| Gross Profit | $42.5 million | $30.5 million | $14.9 million | $11.0 million |
| Gross Margin | 67% | 65% | 65% | 64% |
| Net Income | $11.5 million | $7.6 million | $4.4 million | $3.1 million |
| Diluted EPS | $0.74 | $0.51 | $0.28 | $0.21 |
| Operating Cash Flow | $14.3 million | $3.0 million | N/A | N/A |
| Cash & Equivalents | $10.8 million | $11.8 million | $10.8 million | $11.8 million |
| Total Debt (Current) | $0.1 million | $0.2 million | $0.1 million | $0.2 million |
| Working Capital | $29.1 million | $32.8 million | $29.1 million | $32.8 million |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 34% year-over-year for the nine-month period, driven by increased unit sales of flow generators and accessories in North and Latin America, and to a lesser extent, Europe.
- Profitability: Gross profit margins improved to 67% (9-month) and 65% (quarterly) due to higher sales of higher-margin products and improved manufacturing efficiencies.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses rose 33% year-over-year (9-month) primarily due to an increase in sales and administrative personnel from 136 to 197. However, SG&A as a percentage of revenue declined due to economies of scale.
- Capital Expenditures: Capital expenditures surged to $17.9 million for the nine months ended March 31, 1999, compared to $8.3 million in the prior year. This increase is largely attributed to the construction of a new Australian manufacturing facility.
- Other Income: Other income (expenses) net declined due to the absence of a one-time $1.25 million licensing fee receipt from Invacare Corporation in March 1998, partially offset by reduced foreign currency losses.
Guidance, Outlook, and Risks
- Liquidity: The company anticipates expending approximately $2.0 million over the next three months for the new manufacturing facility and computer systems, funded by operating cash flows and existing resources.
- Year 2000 Compliance: The company is implementing the Oracle Applications Enterprise package to ensure Year 2000 compliance, with completion expected by September 30, 1999. Estimated costs are $2.0 million for the system upgrade and $100,000 for compliance. Risks remain regarding third-party supplier readiness.
- Legal Proceedings: Significant litigation exists with Respironics, Inc. regarding patent infringement in the U.S. and unfair trade practices in Australia. The company faces potential damages of approximately $1 million in Australia and ongoing legal costs. Two summary judgment motions favoring Respironics have been granted in the U.S., with the company intending to appeal.
- Market Risk: The company has significant exposure to the Australian dollar and other foreign currencies, managed through a hedging program involving forward contracts and options.
- Accounting Changes: The company has not yet determined the impact of SFAS No. 133 (Accounting for Derivative Instruments), effective September 30, 1999.
Investor Verification Checklist
- Verify the status and potential financial impact of the ongoing patent litigation with Respironics, Inc., specifically the appeal of summary judgment rulings in the U.S.
- Confirm the timeline and cost overruns associated with the new Australian manufacturing facility construction.
- Monitor the effectiveness of the foreign currency hedging program given the company's significant exposure to the Australian dollar.
- Assess the readiness of key third-party suppliers for Year 2000 compliance to mitigate operational disruption risks.
- Review the adoption impact of SFAS No. 133 on future financial statements regarding derivative instruments.